Research Keyword: NMDA receptor antagonism

Exploring the Therapeutic Potential of Ketamine and Psilocybin in Comparison to Current Treatment Regimens for Treatment-Resistant Depression, Mood Disorders, and Post-traumatic Stress Disorder in the Pediatric Population: A Narrative Review

mycolabadmin

This review examines two emerging psychiatric treatments—ketamine and psilocybin—for treating hard-to-treat mental health conditions in children and teenagers. Both work by affecting brain chemicals differently than traditional medications and can provide rapid symptom relief, sometimes within hours or days rather than weeks. The study found promising results for depression, anxiety, PTSD, and bipolar disorder, though researchers emphasize that more studies are needed to ensure these treatments are safe for developing brains and that careful ethical guidelines must be established.

Read More »

Addressing blinding in classic psychedelic studies with innovative active placebos

mycolabadmin

This research paper discusses how scientists can better test whether psychedelic drugs actually work by improving the way they conduct clinical trials. A major problem is that psychedelic drugs produce obvious effects that make it easy for patients and researchers to figure out who received the real drug versus a fake one. The authors recommend using different types of drugs as placebos that produce similar effects without being therapeutic themselves, such as certain existing medications. By using these better-designed placebos along with other strategies, future research can more definitively prove whether psychedelics truly help treat depression, chronic pain, and other conditions.

Read More »

New and emerging pharmacologic treatments for MDD

mycolabadmin

Major depressive disorder affects millions worldwide and current antidepressants often don’t work well or take weeks to be effective. Researchers have developed exciting new treatments that work through different brain mechanisms and show promise for rapid symptom relief. These include nasal spray ketamine (approved 2019), oral medications like zuranolone (approved 2023), and investigational treatments including psilocybin, which show benefits especially for treatment-resistant cases. While many show great promise, more research is needed on long-term safety and how to make them widely available.

Read More »

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

mycolabadmin

This comprehensive review examines how psychedelic substances, from magic mushrooms to LSD, are being studied as treatments for addiction. After decades of restriction, researchers are rediscovering what indigenous cultures have known for thousands of years: these substances can help people overcome alcohol, drug, and tobacco addiction. The research shows promising results, particularly when combined with therapy, with abstinence rates significantly higher than traditional treatments.

Read More »
Scroll to Top